Pharma News

$FDA Approves New Combination Therapy for Relapsed or Refractory Multiple Myeloma$

6 March 2026

FDA Approves New Combination Therapy for Relapsed or Refractory Multiple Myeloma

The U.S. Food and Drug Administration has approved a new treatment combination of teclistamab‑cqyv with daratumumab and hyaluronidase‑fihj for adult patients with relapsed or refractory Multiple Myeloma. The approval offers a new therapeutic option for patients whose disease has returned or stopped responding after earlier treatments.

5 March 2026

CDSCO Issues Alert After Theft of Sanofi Lantus Insulin Pens During Transit

India’s drug regulator has issued a public advisory after a consignment of insulin pens manufactured by Sanofi India Limited was reported stolen during transportation, raising concerns about potential risks if the products enter the market through unauthorized channels.

5 March 2026

Moderna Settles Vaccine Patent Dispute with 950 Million USD Deal

Biotechnology company Moderna has announced a major settlement to resolve global patent litigation with Arbutus Biopharma Corporation and Genevant Sciences GmbH over technology used in its mRNA vaccines. The agreement settles all ongoing lawsuits worldwide related to the companies’ disputes.

5 March 2026

Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease

The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD).

5 March 2026

US FDA Approves Glenmark’s Generic Fluticasone Propionate Inhaler for Asthma Treatment

Glenmark Specialty SA has received final approval from the U.S. Food and Drug Administration for Fluticasone Propionate Inhalation Aerosol USP

5 March 2026

CDSCO Announces Faster NOC Process for Drug Testing Before Approval

The regulator has announced that companies will now receive the No Objection Certificate, NOC more quickly, helping to streamline regulatory procedures and reduce approval timelines.

2 March 2026

Study Links Faulty Dopamine Packaging to Parkinson’s Progression

New research from Ludwig-Maximilians-Universität München (LMU) reveals that improper handling of the neurotransmitter dopamine within brain cells may play a critical role in worsening symptoms of Parkinson’s disease. The discovery provides fresh insights into how the disease damages neurons and points toward potential new treatment strategies.

2 March 2026

New Study Shows Single Dose of Non-Prescribed Adderall Can Sharply Raise Heart Rate and Blood Pressure

A new study by researchers at the Mayo Clinic has found that a single 25 mg dose of Adderall, when taken without a prescription, can cause significant increases in both heart rate and blood pressure in healthy young adults. The findings raise important questions about the cardiovascular effects of using this stimulant medication outside of medical supervision.

2 March 2026

Novo Nordisk Announces Euro 432 Million Expansion of Athlone Manufacturing Facility

March 2, 2026: In a strategic move to support global demand for oral GLP-1 therapies, Novo Nordisk has revealed plans to invest 432 million euro (approximately DKK 3.2 billion) in expanding its manufacturing operations in Athlone, Ireland.

The investment will significantly increase capacity at Novo Nordisk’s tablet production facility located in Monksland, Athlone, with upgrades aimed at broadening the company’s ability to produce current and future oral GLP-1 medicines. These medicines, used for treating conditions such as diabetes and obesity, have seen rising global demand.

28 February 2026

Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy

Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens, the generic equivalent of Saxenda® (liraglutide injection).

Search

FDA Approves New Combination Therapy for Relapsed or Refractory Multiple Myeloma

RECOMMENDED POSTS

Subscribe with us

Jobs by Category